Proven drugs, reformulated as long-acting injectables and patches.

Proven drugs, reformulated as long-acting injectables and patches.

Extentus Pharma develops long-acting injectable and patch formulations of approved medicines, converting drugs constrained by daily oral regimens into assets with extended dosing intervals, defined regulatory pathways, and clear strategic value.

long-acting injectable and patch formulations of approved medicines
  • A Repeatable Productisation Model
    A platform engine applied across multiple programmes. Known APIs, delivery innovation, and a structured path to human data in each case.
  • Capital-Efficient to the Buy Point
    Development is scoped to the first strategic inflexion: human PK and safety data. Late-stage development and commercial execution are structured for partner or acquirer engagement.
  • A Diligence-Ready Asset Package
    Each programme is built to a defined standard. CMC feasibility, translational PK, local tolerability, and a credible regulatory plan designed to support option-to-license, asset sale, or company-level transaction.

Extentus selects programmes where the clinical rationale for long-acting delivery is well-established, the regulatory pathway is well precedented, and the path to a strategic transaction is clear. The platform generates multiple diligence-ready programmes from the same productisation infrastructure. LAI Abiraterone leads as the near-term priority, with partner-driven LAI options retained as material platform upside at minimal additional capital outlay.

A Focused Pipeline

Owned programmes in oncology and dermatology, led by LAI Abiraterone, with partnered programmes extending platform value.

A De-risking Platform

Known active ingredients, a disciplined candidate-selection science, and a structured path to human data applied across every programme.

A Clear Regulatory Route

Where applicable, the FDA 505(b)(2) pathway supports approval by building on an approved drug’s established record.

Extentus selects programmes where the clinical rationale for long-acting delivery is well-established, the regulatory pathway is well precedented, and the path to a strategic transaction is clear. The platform generates multiple diligence-ready programmes from the same productisation infrastructure. LAI Abiraterone leads as the near-term priority, with partner-driven LAI options retained as material platform upside at minimal additional capital outlay.

Many proven medicines are limited not by the drug, but by how often it has to be taken.

Extentus reformulates approved drugs as long-acting injectables and patches, turning medicines held back by daily dosing into differentiated, partner-ready assets across multiple indications.